Dr. Explains - The Truths about Mots-C Nobody is Talking About
A primary care doctor gives a nine-minute overview of MOTS-c: what it is, when the body makes it, the research she cites, and the risks she raises.
With Dr. Ashley Froese (primary care doctor)
Key moments
Tap a moment to play the video from there.
- 0:00Why MOTS-c is interestingFroese frames MOTS-c as a poorly understood longevity peptide and lists the claims she will cover, including an age-related decline in levels.
- 0:30Credentials and disclaimersShe introduces herself as a primary care doctor and states that the video is educational and that MOTS-c is not FDA-approved for human use.
- 1:00What MOTS-c isShe describes a 16-amino acid peptide made from mitochondrial DNA, discovered in 2015, that works as a signaling molecule.
- 1:30What triggers its productionFroese says exercise, fasting, low oxygen, and heat or cold exposure raise MOTS-c, and that levels decline with age.
- 3:04How it works in cellsShe explains AMPK activation, insulin sensitivity, fatty acid oxidation, and the formation of new mitochondria.
- 4:36Preclinical research she citesShe walks through studies on obesity, insulin resistance, aging, damaged muscle, heart thickness, and bone loss after induced menopause.
- 6:08Human studies and associationsShe cites a study from Japan linking higher MOTS-c with lower myostatin, and lower levels in PCOS, sleep apnea, and ovarian cancer.
- 7:09Risks and caveatsFroese reports welts, jitteriness, anxiety, blood sugar crashes, overlap with other AMPK activators, and a theoretical cancer concern.
- 8:13Outlook and course promotionShe says it is a waiting game for wider access, then promotes her Peptide Mastery course.
What the video says
Dr. Ashley Froese, a primary care doctor who runs the channel This Is Not Covered, presents MOTS-c as a peptide that deserves more accurate coverage. She opens with a disclaimer that the video is educational, that she is not the viewer's doctor, and that MOTS-c is not FDA-approved for human use.
She describes MOTS-c as a 16-amino acid peptide encoded in mitochondrial DNA and discovered in 2015. According to Froese, the body makes it at a low baseline level and produces more under metabolic stress, including exercise, fasting or caloric restriction, low oxygen, and heat or cold exposure. She says levels fall with age, and that this may contribute to weaker mitochondrial signaling and less metabolic flexibility. She explains its signaling role as activating AMPK, which she calls the body's energy sensor, and links that to insulin sensitivity, fat oxidation, and the building of new mitochondria. She says this is why it has a reputation as an exercise mimetic.
The middle of the video lists research she has read. Most of it is preclinical: studies on diet-induced obesity and insulin resistance, age-related physical decline, damaged muscle, heart wall thickness in diabetes, and bone loss after induced menopause. She also cites human observational findings, including an association between higher MOTS-c and lower myostatin, and lower levels in women with PCOS, in people with severe sleep apnea, and in women with ovarian cancer.
She then turns to risks. She reports, from real-world accounts rather than trials, injection-site welts, jitteriness, anxiety, and blood sugar crashes. She notes that other AMPK activators such as metformin and berberine would need to be considered, and she raises an unproven concern about cancer cells. She says long-term human effects are unknown. The video closes with a promotion of her own peptide course.
On each compound
MOTS-c1:00
Froese describes MOTS-c as a mitochondrial signaling peptide that she says activates AMPK and supports insulin sensitivity, fat oxidation, and mitochondrial growth. She cites mostly preclinical studies and some human associations, and she reports injection welts, jitteriness, and blood sugar crashes from real-world accounts.
See how your DNA reads MOTS-c“MOTS-c is not currently FDA-approved for human use”
What this video doesn’t settle
- Most of the efficacy research described is preclinical, and the video does not present a human trial of MOTS-c given as a peptide.
- The human findings are associations in blood levels, which do not show that raising MOTS-c would change those conditions.
- Side effects come from unnamed real-world reports, with no data on how common they are.
Questions this video answers
What is MOTS-c and what does it do?
Froese describes it as a 16-amino acid peptide made from mitochondrial DNA and discovered in 2015. She says it acts as a signaling molecule that activates AMPK, which she links to insulin sensitivity, fat oxidation, new mitochondria, and muscular endurance.
What triggers the body to make more MOTS-c?
According to Froese, production rises during and after exercise, and with fasting or caloric restriction, low oxygen, and heat or cold exposure. She says levels are higher in youth and decline with age.
What are the side effects of MOTS-c according to this video?
Froese says real-world reports include large injection welts that last days or weeks, feeling jittery or anxious, and blood sugar crashes. She also mentions a theoretical, unproven concern about cancer cells and says long-term human effects are unknown.
Is MOTS-c FDA-approved?
Froese states that MOTS-c is not currently FDA-approved for human use and that the FDA says people are not supposed to be buying and using it. She says she hopes access improves, and mentions 2027.
Is there human research on MOTS-c?
Froese cites observational findings in people: higher natural levels linked to lower myostatin, and lower levels in women with PCOS, in people with severe sleep apnea, and in women with ovarian cancer. Most of the intervention research she describes is preclinical.
Video by This Is Not Covered - Dr. Ashley Froese on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
